Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director · President & CEO | November 07, 2023 | November 09, 2023 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | February 03, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date November 07, 2023 · Filed November 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,758 |
Ending reported balance
After 2023-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-11-07 · Exercise / conversion · Acquired 1,172 · Balance 17,930 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 2 · 2023-11-08 · Sale · Disposed 172 · Balance 17,758 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,236 |
Reported balance
After 2023-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-07 · Exercise / conversion · Disposed 1,172 · Balance 15,236 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F4: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Serina Therapeutics, Inc.
Report date February 03, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.76 · Expires 2036-02-03 | Direct | 92,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 92,000 · Balance 92,000 F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:01 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001180763-26-000005 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001180763-26-000002 · wk-form4_1771334683.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:27 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 25,000 | $4.79 Strike: $4.79 | $119,750.00 |
DisclosureSEC source: 0001562180-25-004902 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-16 Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $5.52 Strike: $5.52 | $88,320.00 |
DisclosureSEC source: 0001562180-24-005359 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-25 Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 22:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 295,300 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001493152-24-015067 · ownership.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,300 Underlying: Common Stock · 295,300 shares Expires 2034-04-15 F1 · derivative.exercise_date: The stock options vest as to 25% of the underlying shares on October 15, 2024 and thereafter in substantially equal monthly installments such that the stock options shall be fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 01:31 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | SaleCommon Stock | 172 | $0.33 | $56.76 |
DisclosureSEC source: 0001694665-23-000176 · wk-form4_1699493502.xml · nonDerivative · entry 2 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,758 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 01:31 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionRestricted Stock Units · Derivative | 1,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000176 · wk-form4_1699493502.xml · derivative · entry 3 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,236 Underlying: Common Stock · 1,172 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 01:31 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionCommon Stock | 1,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694665-23-000176 · wk-form4_1699493502.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 20:02 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | SaleCommon Stock | 1,996 | $3.94 | $7,864.24 |
DisclosureSEC source: 0001694665-23-000160 · wk-form4_1696017728.xml · nonDerivative · entry 2 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,758 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $3.92 to $3.94, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:02 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000160 · wk-form4_1696017728.xml · derivative · entry 4 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:02 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000160 · wk-form4_1696017728.xml · derivative · entry 3 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:02 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694665-23-000160 · wk-form4_1696017728.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 00:43 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | SaleCommon Stock | 342 | $9.51 | $3,252.42 |
DisclosureSEC source: 0001694665-23-000135 · wk-form4_1691628193.xml · nonDerivative · entry 2 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,754 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $9.08 to $9.55, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:43 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionRestricted Stock Units · Derivative | 1,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000135 · wk-form4_1691628193.xml · derivative · entry 3 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,408 Underlying: Common Stock · 1,171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:43 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionCommon Stock | 1,171 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694665-23-000135 · wk-form4_1691628193.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:11 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005475 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:01 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001694665-23-000081 · wk-form4_1686600107.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2033-03-16 F1 · kind: Om March 17, 2023, the reporting person was granted an option to purchase 1,000,000 shares of the issuer's common stock subject to certain conditions, including the approval of the amendment and restatement of the Evelo Biosciences, Inc. 2018 Incentive Award Plan (the "2018 Plan") by stockholders at the issuer's 2023 Annual Meeting of Stockholders. The stockholders approved the amendment and restatement of the 2018 Plan on June 8, 2023. F2 · derivative.exercise_date: The option vests in forty-eight (48) substantially equal installments at the end of each monthly anniversary of February 7, 2023, subject to the reporting person's continued service to the issuer on each such vesting date. Read SEC document |
| May 08, 2023 Filed May 11, 2023 01:31 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | SaleCommon Stock | 3,537 | $0.13 | $443.89 |
DisclosureSEC source: 0001694665-23-000051 · wf-form4_168376866026508.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,512 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $0.12 to $0.13, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 20:09 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionRestricted Stock Units · Derivative | 23,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000043 · wf-form4_168366293877236.xml · derivative · entry 2 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,563 Underlying: Common Stock · 23,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| May 07, 2023 Filed May 9, 2023 20:09 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionCommon Stock | 23,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694665-23-000043 · wf-form4_168366293877236.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 07, 2023 Filed May 10, 2023 21:11 UTC Amendment | Evelo Biosciences, Inc. EVLO · Entity 108468 | Exercise / conversionRestricted Stock Units · Derivative | 23,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000046 · wf-form4a_168375309729647.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,563 Underlying: Common Stock · 23,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:38 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantRestricted Stock Units · Derivative | 375,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001694665-23-000015 · wf-form4_167597869228821.xml · derivative · entry 2 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. F2 · derivative.expiration_date: The Restricted Stock Units vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:38 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 1,125,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001694665-23-000015 · wf-form4_167597869228821.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125,000 Underlying: Common Stock · 1,125,000 shares Expires 2033-02-07 F1 · derivative.exercise_date: The options vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to the reporting person's continued service to the issuer on each such vesting date. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 00:59 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GiftCommon Stock | 47,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-006673 · primarydocument.xml · nonDerivative · entry 2 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,061 F1 · kind: Represents a bona fide gift of Common Stock to a non-profit educational institution. Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 00:59 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 82,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001562180-22-006673 · primarydocument.xml · derivative · entry 3 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,188 Underlying: Common Stock · 82,000 shares Expires 2027-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on July 25, 2018, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option was fully vested. Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 00:59 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 82,000 | $0.73 | $59,860.00 |
DisclosureSEC source: 0001562180-22-006673 · primarydocument.xml · nonDerivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 00:59 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001562180-22-005315 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-20 Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:42 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001694665-22-000011 · wf-form4_164280134938377.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:53 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 12,530 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-21-004933 · primarydocument.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,530 Underlying: Common Stock · 12,530 shares Expires 2031-07-12 F1 · derivative.exercise_date: The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:34 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001694665-21-000026 · wf-form4_161195965391476.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 21:17 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001694665-20-000004 · wf-form4_158041901328960.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 13:54 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001694665-19-000004 · wf-form4_154764683002118.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: These options will vest as to 25% of the total grant on the first anniversary of the grant date with the remainder vesting in equal quarterly installments over a three-year period thereafter, subject to continued employment on such dates. Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:06 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option · Derivative | 145,869 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012420 · doc4.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,869 Underlying: Common Stock · 145,869 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the grant date and vests in equal quarterly installments over a three year period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.